AAM Warns Over Biden Budget Plans To Extend IRA
Announcement Adds To Uncertainty For US Off-Patent Drug Development
US generics and biosimilars association the AAM has offered a frosty response to budget plans announced by the Biden administration that include expanding the scope of price negotiation under the Inflation Reduction Act.
You may also be interested in...
AAM’s Baeder Takes A Focused Approach To Articulating Industry Priorities
Christine Baeder, Teva’s chief operating officer for US generics and biosimilars, was named chair of the AAM’s board in February. Speaking with Generics Bulletin, she sets out her priorities against the backdrop of a US generics industry that is now at an “inflection point” for sustainability.
AAM Names Teva’s Baeder Chair As It Kicks Off Annual Meeting
Christine Baeder has become chair of the AAM’s board, with the Teva executive welcomed to role as the US industry association kicked off its annual Access! conference in Orlando.
Leonard Resignation Leaves AAM Looking For New Leadership
Dan Leonard has announced his resignation as president and CEO of the US Association for Accessible Medicines. He will be replaced on an interim basis by the group’s vice president for sciences and regulatory affairs, David Gaugh.